BAI-BACE for Advanced Lung Squamous Cell Carcinoma

Bronchial arterial infusion plus bronchial arterial chemoembolization (BAI-BACE) has been reported as non-first-line therapy to treat lung cancer in many hospitals in China. BAI, which uses chemotherapeutic drugs directly injected into the tumor and achieved a high concentration in a short time to kill the tumor. Then BACE could seal off the tumor vessels. In this study, we aim to describe the efficacy and safety of BAI-BACE as non-first-line for advanced lung squamous cell carcinoma.

Trial Details

NCT ID
NCT06377735
Phase
NA
Sponsor
Sun Yat-sen University
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • BAI-BACE
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Squamous cell carcinoma diagnosed by pathology, and central location by imaging;
  • Age 18-80;
  • Patients failed to the standard first-line or second-line treatment;
  • Tumors limited in the chest;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →